Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

Authorised

- Praziquantel
- Milbemycin oxime

Product identification

Medicine name:
Alpramil 5 mg/50 mg tablets for dogs weighing at least 0.5 kg

Active substance:
Praziquantel

Milbemycin oxime

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Praziquantel
50.00 milligram(s) / 1.00 Tablet

Milbemycin oxime

5.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QP54AB51

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Finland

Package description:
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
Box with 25 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 4 tablets.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 2 tablets.
Box with 10 OPA/Aluminium/PVC-Aluminium blisters each containing 1 tablet.
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 4 tablets.
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 2 tablets
Box with 1 OPA/Aluminium/PVC-Aluminium blister containing 1 tablet.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Hybrid application (Article 13(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Alfasan Nederland B.V.

Marketing authorisation date:
1/09/2025

Manufacturing sites for batch release:
Lelypharma B.V.
Alfasan Nederland B.V.

Responsible authority:
Finnish Medicines Agency

Authorisation number:
38892

Date of authorisation status change:
1/09/2025

Reference member state:
Netherlands

Procedure number:
NL/V/0364/004

Concerned member states:
Belgium Bulgaria Croatia Cyprus Czechia Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain

United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

NL_V_0364_004-006_DC Milpramax tablets for dogs-Final PuAR.pdf